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MaOBJECTIVES This study sought to assess the presence and extent of focal and diffuse fibrosis in heart failure in patients
with preserved ejection fraction (HFpEF) compared to asymptomatic control subjects, and the relationship of fibrosis to
clinical outcome.
BACKGROUND Myocardial fibrosis has been implicated in the pathophysiology of HFpEF.
METHODS In this prospective, observational study, 140 subjects of similar age and sex (HFpEF: n ¼ 96; control
subjects: n ¼ 44; 73  8 years of age; 49% males) underwent cardiac magnetic resonance imaging. Late gadolinium-
enhanced (LGE) imaging and T1 mapping to calculate myocardial extracellular volume indexed to body surface area
(iECV) were used to assess fibrosis.
RESULTS Patients with HFpEF had more concentric remodeling and worse diastolic function. Focal fibrosis was more
frequent in HFpEF subjects (overall: n ¼ 49; infarction: n ¼ 17; nonischemic cases: n ¼ 36; mixed patterns: n ¼ 4) than in
control subjects (overall: n ¼ 3). Diffuse fibrosis was also greater in HFpEF subjects than control subjects (iECV: 13.7  4.4
ml/m2 versus 10.9  2.8 ml/m2; p < 0.0001). During median follow-up (1,429 days), there were 42 composite events
(14 deaths; 28 heart failure hospitalizations) in cases of HFpEF. Myocardial infarction revealed on LGE imaging was a
predictor of outcomes on univariate analysis only. With multivariate analysis, iECV (hazard ratio [HR]: 1.689; 95%
confidence interval [CI]: 1.141 to 2.501; p ¼ 0.009) was an independent predictor of outcome along with mitral peak
velocity of early filling (E)-to-early diastolic mitral annular velocity (E’) (E/E0) ratio (HR: 1.716; 95% CI: 1.191 to 2.472;
p ¼ 0.004) and prior HF hospitalization (HR: 2.537; 95% CI: 1.090 to 5.902; p ¼ 0.031). iECV was also significantly
associated with ventricular/left atrial remodeling and renal dysfunction: right ventricular end-diastolic volume indexed
(r ¼ 0.456; p < 0.0001), left ventricular mass/volume (r ¼ 0.348; p ¼ 0.001), maximal left atrial volume indexed
(r ¼ 0. 269; p ¼ 0.009), and creatinine (r ¼ 0.271; p ¼ 0.009).
CONCLUSIONS Both focal and diffuse myocardial fibrosis are more prevalent in HFpEF subjects than in control
subjects of similar age and sex. iECV significantly correlates with indices of ventricular/left atrial remodeling and renal
dysfunction and is an independent predictor of adverse outcome in HFpEF. (Developing Imaging and plasMa biOmarkers
iN Describing Heart Failure With Preserved Ejection Fraction [DIAMONDHFpEF]; NCT03050593)
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ABBR EV I A T I ON S
AND ACRONYMS
BNP = B-type natriuretic
peptide
CMR = cardiac magnetic
resonance imaging
ECV = extracellular volume
iECV = indexed extracellular
volume
HFpEF = heart failure with
preserved ejection fraction
LAVImax = maximal left atrial
volume indexed
LGE = late gadolinium
enhancement
LV = left ventricle
RV = right ventricle
MI = myocardial infarction
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H eart failure with preserved ejectionfraction (HFpEF) accounts for upto half of all heart failure patients
in the community, and outcomes remain
poor (1). Current prognostic markers in
HFpEF relate largely to clinical and echocar-
diographic parameters (2,3). However, car-
diac magnetic resonance (CMR) imaging is
the recognized gold standard for most of the
imaging parameters that comprise the latest
guidance for assessing HFpEF (4). Both focal
fibrosis (myocardial infarction [MI] and
“nonischemic” fibrosis) and interstitial
myocardial fibrosis have been implicated in
the pathophysiology of HFpEF by promoting
adverse ventricular remodeling, increasing
myocardial stiffness, and in turn, causing
diastolic dysfunction (5). Focal fibrosis (6),including MI (7), can be detected by late gadolinium
enhanced (LGE) imaging, and pre- and post-contrast
T1 mapping allow calculation of myocardial extracel-
lular volume (ECV), a surrogate marker of interstitial
fibrosis (8,9). LGE is associated with reduced survival
across a range of clinical conditions (6), including
heart failure with reduced ejection fraction, hypertro-
phic cardiomyopathy, and HFpEF, in a single study
with a small sample size (10).
In HFpEF, however, the pattern of interstitial
fibrosis tends to be more diffuse, which cannot be
detected using the LGE technique (6,9). CMR T1
parametric mapping techniques enable quantification
of the extracellular matrix (9), a surrogate marker of
diffuse fibrosis, and have been validated histologi-
cally (8). To date, only 4 small prospective HFpEF
outcome studies (11–14), including only 1 study (13)
with phenotyped, healthy control reference groups
have evaluated diffuse fibrosis using either post-
contrast T1 times (12) or ECV (11,13,14). Recently, in
a further refinement, iECV (ECV indexed to body
surface area) was related to outcomes in patients with
aortic stenosis (15), but this has not been studied in
HFpEF and related to clinical outcomes.
The present study sought to evaluate whether
there were differences between the presence and
extent of both focal and diffuse fibrosis in HFpEF
subjects and those in matched control subjects
without heart failure and to determine whether
fibrosis provided additional prognostic value beyond
conventional clinical and echocardiographic indices.
METHODS
PATIENT POPULATION. HFpEF patients were
recruited as part of a prospective, observationalcohort study conducted at a tertiary cardiac center
and were compared with asymptomatic control sub-
jects. HFpEF inclusion criteria were clinical or radio-
graphic evidence of HF, left ventricular ejection
fraction (LVEF) >50% on transthoracic echocardiog-
raphy, and $18 years of age. Exclusion criteria were
documented MI in the preceding 6 months, suspected
or confirmed cardiomyopathy (e.g., hypertrophic
cardiomyopathy, amyloid) or constrictive pericar-
ditis, severe native valve disease, noncardiovascular
life expectancy <6 months, severe pulmonary disease
(a predicted forced expiratory volume in 1 s of <30%
or a predicted forced vital capacity of <50%), esti-
mated glomerular filtration rate of <30 ml/min/m2,
and contraindications to CMR. Asymptomatic control
subjects of similar age and sex without known cardiac
disease were recruited. Hypertensive control subjects
(n ¼ 19) were not excluded because hypertension is
highly prevalent in the general population (16), and
the authors wanted to identify factors that were
different between those with and those without
HFpEF.
All subjects were examined for medical history, a
review of medical notes, blood sample analysis,
transthoracic echocardiography, and CMR during the
same visit. The study was approved by the National
Research Ethics Service. Written informed consent
was provided by all subjects prior to participation.
BLOOD SAMPLES. Blood was sampled for B-type
natriuretic peptide (BNP) (immunoassay, Siemens,
Erlangen, Germany), hematocrit, hemoglobin, and
renal function.
TRANSTHORACIC ECHOCARDIOGRAPHY. Echo-
cardiography was performed as previously reported
(17), using an iE 33 system (Philips Medical Systems,
Best, The Netherlands). LVEF for study inclusion was
calculated using the biplane method or estimated
visually where endocardial border definition was
poor.
CMR PROTOCOL. The CMR protocol was similar to
that previously published by the present authors (17).
All scans were performed using a 3-T scanner
(Siemens Skyra, Erlangen, Germany) with an 18-
channel cardiac coil. Briefly, the protocol consisted
of standard breath-held steady-state free precession
cine imaging; basal, mid-ventricular, and apical
short-axis modified Look-Locker inversion recovery
(MOLLI) images pre- and post-contrast; and LGE im-
aging. The MOLLI sequence (18) was performed with
the following parameters: breath-held or free
breathing, single-shot sequence, 3,5(3)3(3)5 sampling
pattern, 8-mm slice thickness, 300  400-mm field of
view, 50-flip angle, 120-ms minimum TI, and 80-ms
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . - , N O . - , 2 0 1 9 Kanagala et al.
- 2 0 1 9 :- –- Focal and Diffuse Fibrosis in HFpEF and Outcomes
3
increments of inversion time. Similar techniques
were used to minimize artifacts, as previously re-
ported by the present authors, and the T1 times were
calculated from motion-corrected parametric maps
with excellent reproducibility (19). LGE was per-
formed at least 10 min after an injection of
0.15 mmol/kg contrast (Gadovist, Bayer Healthcare,
Berlin, Germany) was administered in the same slice
positions as the cine images. A 2D phase-sensitive
inversion recovery (PSIR) gradient echo sequence
was used, and the optimal TI was determined
following a standard Look-Locker sequence. Single-
shot multislice acquisitions were obtained in pa-
tients with poor breath-hold technique or arrhythmia.
CMR IMAGE ANALYSIS. Images were analyzed by a
single observer (P.K.), who was blinded to all clinical
data, using CVI42 software (Circle Cardiovascular
Imaging, Calgary, Canada). Ventricular volumes, EF,
and LV mass (excluding papillary muscles) were
calculated from the short-axis cine stack (17). Left
atrial volumes were calculated using the biplane
method, excluding the appendage and pulmonary
veins (20). All volumetric and mass data were indexed
to body surface area. Indexed LV end-diastolic mass
was divided by 1.05, the specific density of myocar-
dial tissue, to derive myocardial volume.
LGE ANALYSIS OF FOCAL MYOCARDIAL FIBROSIS.
As described previously (19), qualitative assessment
of LGE images was first undertaken by 2 experienced
observers (P.K., A.S.H.C.) to achieve consensus for
identifying the presence and pattern of LGE (i.e.,
ischemia vs. nonischemia). If there was disagree-
ment, a third observer (G.P.M.) adjudicated. Fibrosis
was considered present if LGE was visualized on both
short- and orthogonal long-axis LGE images. Inser-
tion point fibrosis was included in the analysis. The
full-width half-maximum technique was then used to
quantify fibrosis (21). Examples of focal fibrosis and
measurements are shown in Figure 1. In some cases,
both of the patterns of fibrosis were evident in the
same subject and were therefore reanalyzed sepa-
rately, that is, MI was quantified first, and non-
ischemic fibrosis was analyzed subsequently after
drawing exclusion zone contours around MI areas.
ANALYSIS OF DIFFUSE MYOCARDIAL FIBROSIS.
Only the mid-ventricular slice MOLLI images were
analyzed to minimize errors (19,22). As described
previously by the present authors (19) (Figure 2), re-
gions of interest were drawn in the myocardium and
blood pool to generate native and post-contrast T1
values from parametric maps. The software provided
T1 results for 6 mid-ventricular segments (7–12)corresponding to the American Heart Association
nomenclature after use of the anterior RV insertion
point as a reference marker. After blood hematocrit
values were entered, the software generated
segmental ECV values (19). Segments with MI and
artifacts were excluded from final T1 and ECV calcu-
lation, and segmental values were then averaged.
Regions of focal nonischemic fibrosis were included
in the ECV calculations, consistent with other studies
(9,22). iECV was derived using the formula:
[ECV (%)  left ventricular end-diastolic myocardial
volume indexed to body surface area] (15).
OUTCOME DATA. The clinical endpoint was a com-
posite of mortality or repeat hospitalization for HF.
Hospital databases and patient records were selected
to obtain outcome data. Patients were followed for a
minimum of 6 months post-study entry.
STATISTICAL ANALYSIS. Statistical tests were per-
formed using SPSS version 22 software (IBM Corp.,
Armonk, New York). Continuous data were assessed
for normality by using histograms, Q-Q plots, and the
Shapiro-Wilk test. Summary data are mean  SD or
median (25% to 75% interquartile range [IQR]).
Between-group differences were compared using the
t-test, the Mann-Whitney U test, and the chi-square
test as appropriate. BNP and creatinine concentra-
tions were log10 transformed before analysis.
Kaplan-Meier analysis was undertaken to calculate
event rates. The log-rank test was used to test dif-
ferences in survival curves. Univariate Cox regression
modeling was initially performed to identify variables
associated with outcome. Variables tested were those
shown to have prognostic importance from published
reports with the intention of preventing model over-
fitting (2,3). Covariates associated with the endpoint
at a p value of <0.10 were then entered into subse-
quent multivariate analyses to identify independent
predictors, using both backward and forward step-
wise elimination methods. Furthermore, multivariate
models were limited to no more than 4 parameters,
allowing for approximately 1 parameter per 10 com-
posite events. Four separate clinically relevant
multivariate models were generated, including a final
model incorporating the strongest predictors.
Continuous variables were z-standardized to enable
comparison of hazard ratios (HR) on the basis of 1 SD
increase in the predictor variable. The combined
accuracy of the independent variables to predict
events was then tested by receiver operator charac-
teristics (ROC) analysis.
Pearson’s correlation tests were performed to
check for potential associations between iECV and




Late gadolinium enhancement images demonstrating (A) focal fibrosis (red arrows) and (B) corresponding, quantified burden (highlighted in
yellow) using the full width half-maximum technique: 1 ¼ insertion point fibrosis; 2 ¼ mid-wall fibrosis; 3 ¼ subendocardial myocardial
infarction.
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ECV and other variables. Linear regression modeling
with stepwise selection methods was undertaken to
identify the strongest independent associations. In
cases of collinearity, the variable with the highest
coefficient was entered into multivariate analysis.A p value of <0.05 was considered significant. As-
sessments of intraobserver and interobserver vari-
ability for focal fibrosis and ECV calculation were
undertaken from 10 randomly selected patients, a
minimum of 4 weeks apart (by P.K. and J.R.A.).
FIGURE 2 Calculation of Extracellular Volume
A B
(A) Pre- and (B) post-contrast contours in the mid-myocardial area are indicated by white and red arrows, respectively. The left ventricular
cavity is shown (orange) to enable derivation of T1 values and extracellular volume.
FIGURE 3 Study Recruitment Overview
Confirmed HFpEF agreed to
participate: n = 182
No CMR: n = 27
Claustrophobia (11); Pacemakers (7);
Patient declined (5); Orthopnea (3);
Implantable loop recorder (1)
Confirmed HFpEF who underwent
CMR: n = 155
Excluded post-CMR: n = 15
Hypertrophic cardiomyopathy (10);
Constrictive pericarditis (5)
MOLLI not available: n = 44
Final HFpEF for CMR blinded
analysis: n = 96
Final controls for CMR blinded
analysis: n = 44
MOLLI not available: n = 4




to participate: n = 50
Controls invited: n = 65
Controls who underwent
CMR: n = 48
Suspected HFpEF
invited: n = 662
Flow chart shows recruitment and CMR assessments. CMR ¼ cardiac magnetic resonance imaging; HFpEF ¼ heart failure with preserved
ejection fraction; MOLLI ¼ modified Look-Locker inversion recovery sequence.
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(n ¼ 44) p Value
Demographics
Age, yrs 73  9 73  5 0.784
Males 46 (48) 21 (48) 0.983
Body mass index, kg/m2 34  7 25  3 <0.0001
Clinical findings
Heart rate, beats/min 69  14 68  11 0.614
Systolic blood pressure, mm Hg 146  25 151  24 0.282
Diastolic blood pressure, mm Hg 75  12 80  11 0.025
Sinus rhythm 64 (67) 44 (100) <0.0001
Atrial fibrillation 32 (33) 0 (0) <0.0001
Medical history
Diabetes 48 (50) 0 (0) <0.0001
Hypertension 86 (90) 19 (43) <0.0001
Angina 19 (20) 0 (0) 0.002
Known myocardial infarction 13 (14) 0 (0) 0.010
Asthma or COPD 18 (19) 2 (5) 0.026
Smoking 52 (54) 16 (36) 0.050
Hypercholesterolemia 45 (47) 16 (36) 0.244
Peripheral vascular disease 2 (2) 0 (0) 0.335
TIA or CVA 9 (9) 1 (2) 0.006
Medication
Beta-blocker 68 (71) 1 (2) <0.0001
ACE inhibitor or ARB 82 (85) 9 (20) <0.0001
Aldosterone antagonist 31 (32) 0 (0) <0.0001
Loop diuretic 76 (79) 0 (0) <0.0001
Functional status
NYHA functional class I/II 68 (71) NA NA
NYHA functional class III/IV 28 (29) NA NA
Sera values
Sodium, mmol/l 139.5  3.4 140.2  1.8 0.084
Urea, mmol/l 8.5  3.6 6.1  1.5 <0.0001
Median creatinine, mmol/l (IQR) 87 (71-113) 69 (56-85) <0.0001
Hemoglobin, g/l 129  19 140  14 <0.0001
Hematocrit 38  5 41  4 0.013
Median BNP, ng/l 144 (66-250) 33 (24-44) <0.0001
Values are mean  SD, n (%), or median (interquartile range). The p values are results for the t-test or the chi-
square test.
ACE ¼ angiotensin converting enzyme inhibitor; ARB ¼ angiotensin II receptor blocker; BNP ¼ B-type natri-
uretic peptide; CMR ¼ cardiac magnetic resonance imaging; COPD ¼ chronic obstructive pulmonary disease;
CVA ¼ cerebrovascular accident; HFpEF ¼ heart failure with preserved ejection fraction; NA ¼ not applicable;
NYHA ¼ New York Heart Association; TIA ¼ transient ischemic attack.
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RESULTS
A total of 232 subjects were enrolled (HFpEF n ¼ 182;
control subjects n ¼ 50), of whom 96 patients with
HFpEF and 44 control subjects had complete datasets
including T1 maps. Reasons for exclusion are shown
in Figure 3.
Baseline clinical and imaging characteristics are
summarized in Tables 1 and 2. In the HFpEF group,
there was a high burden of obesity, hypertension,
diabetes, and atrial fibrillation. Nearly one-fifth of the
group had a history of angina or lung disease. More
than two-thirds (71%) had evidence of priorpulmonary congestion on chest radiography, and a
substantial minority (29%) assessed were New York
Heart Association (NYHA) functional class III/IV.
Compared to control subjects, HFpEF patients had
worse renal function, increased LV end-diastolic mass
indexed but not LV volumes and more concentric
remodeling (mass/volume). HFpEF patients also had
higher filling pressures (E/E0), BNP concentrations,
and maximal left atrial volume indexed (LAVImax),
consistent with worse diastolic function.
FOCAL FIBROSIS. Results are shown in Table 2.
Approximately half (n ¼ 49 [51%]) of the HFpEF
cohort had evidence of focal fibrosis (vs. n ¼ 3 [7%] in
the control subjects; p < 0.0001). The predominant
pattern of fibrosis in the HFpEF group was non-
ischemic in 36 patients (38%). MI was present in 17
patients (18%), including 7 patients with previously
unknown MI, but in none of the control subjects. Both
MI and nonischemic fibrosis were present in 4
patients. In those with HFpEF exhibiting LGE hyper-
enhancement, the quantified fibrotic burden was
relatively small: 3% of LV mass (3% ischemic patients
and 2.9% nonischemic patients).
DIFFUSE FIBROSIS. Native T1, post-contrast T1, ECV,
and iECV values in HFpEF subjects were all signifi-
cantly different from those in control subjects, over-
all. Both ECV (27.8%) and iECV (13.7 ml/m2) values
were also elevated in HFpEF subjects compared to
those in hypertensive (24.8%; p ¼ 0.007; 11.3 ml/m2;
p ¼ 0.002) and nonhypertensive (25.7%; p ¼ 0.032;
10.7 ml/m2; p < 0.0001) control subjects. There were
no differences between ECV (p ¼ 0.346) and iECV
(p ¼ 0.505) values in hypertensive control subjects
and those in nonhypertensive control subjects.
INTEROBSERVER AND INTRAOBSERVER ASSESSMENTS.
Data quantification for T1 mapping and LGE are
shown in Supplemental Table 1. Interobserver and
intraobserver variability were excellent for all mea-
surements (intraclass correlation coefficients: >0.95).
OUTCOMES. During median follow-up of 1,429 days
(IQR: 1,157 to 1,657 days), there were 42 events
(14 deaths, 28 HF hospitalizations) in patients with
HFpEF. There were no events in the control group.
PREDICTORS OF CLINICAL OUTCOME. On univariate
analysis (Supplemental Table 2), 10 variables were
associated with adverse outcomes: prior HF hospi-
talization, lung disease, hemoglobin, log BNP, E/E0,
LV mass/volume, LAVImax, MI, ECV, and iECV. The
presence of (or quantified) nonischemic focal fibrosis
was not associated with outcome (p ¼ 0.164 and
p ¼ 0.210, respectively). Kaplan-Meier survival
curves stratified according to quartiles of iECV and
ECV are shown in Figure 4. The highest quartiles of




(n ¼ 44) p Value
Previous chest radiography
Pulmonary edema 68 (71) NA NA
Raised cardiothoracic ratio 65 (68) NA NA
Pleural effusion 33 (34) NA NA
Echocardiography
E/E0 ratio 12.8  4.8 9.0  2.9 <0.0001
CMR volumes, function, and LV mass
LVEF 56  6 58  5 0.406
LVEDVI, ml/m2 78  18 81  14 0.409
LVESVI, ml/m2 34  11 34  8 0.708
LVMI, g/m2 51  13 46  9 0.004
LV mass/volume 0.68  0.15 0.57  0.09 <0.0001
RVEF 54  10 56  6 0.090
RVEDVI, ml/m2 79  20 83  15 0.307
RVESVI, ml/m2 37  14 37  9 0.922
LAVImax, ml/m2 54  27 35  12 <0.0001
LGE focal fibrosis
Total focal fibrosis 49 (51) 3 (7) <0.0001
Total focal fibrosis, g 3.6 (2.0-6.4) 2.5 (0.5-2.6) <0.0001
Total focal fibrosis, % of LV mass 3.0 (2.0-6.3) 2.0 (0.8-3.0) <0.0001
Ischemic pattern 17 (18) 0 (0) <0.0001
Ischemic pattern, % of LV mass 3.0 (2.2-4.6) NA NA
Nonischemic pattern 36 (38) 3 (7) <0.0001
Nonischemic pattern, % of LV mass 2.9 (1.4-6.5) 2.0 (0.8-3.0) <0.0001
T1 mapping of diffuse fibrosis
Native myocardial T1, ms 1,234  73 1,197  91 0.021
Post-contrast myocardial T1, ms 461  63 495  85 0.011
ECV 27.8  4.6 25.3  3.2 <0.0001
iECV, ml/m2 13.7  4.4 10.9  2.8 <0.0001
Values are mean  SD, n (%), or median (IQR).
ECV ¼ extracellular volume; E/E0 ¼ mitral peak velocity of early filling (E) to early diastolic mitral annular
velocity (E’); iECV ¼ indexed extracellular volume; LAVImax¼maximal left atrial volume indexed to body surface
area; LGE ¼ late gadolinium enhancement imaging; LVEF ¼ left ventricular ejection fraction; LVMI ¼ left ven-
tricular end-diastolic mass indexed to body surface area; LVEDVI ¼ left ventricular end-diastolic volume indexed
to body surface area; LVESVI ¼ left ventricular end-systolic volume indexed to body surface area NA ¼ not
applicable; RVEF ¼ right ventricular ejection fraction; RVEDVI ¼ right ventricular end-diastolic volume indexed
to body surface area; RVESVI ¼ right ventricular end-systolic volume indexed to body surface area; other
abbreviations as in Table 1.
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both iECV (>16.8 ml/m2) and ECV (>30.7%) were
associated with the greatest risk of adverse outcome
(log-rank p ¼ 0.017 and 0.009, respectively). On
multivariate analysis (Table 3), iECV remained
significantly associated with outcome in 3 separate
models incorporating clinical factors, markers of
diastolic dysfunction, and LV structural/remodeling
parameters. In a final model consisting of the
strongest predictors overall, iECV (HR: 1.689; 95%
confidence interval [CI]: 1.141 to 2.501; p ¼ 0.009)
remained an independent predictor along with E/E0
(HR: 1.716; 95% CI: 1.191 to 2.472; p ¼ 0.004) and
prior HF hospitalization (HR: 2.537; 95% CI: 1.090
to 5.902; p ¼ 0.031). The final multivariate model
predicted outcomes with an area under the
ROC curve of 0.724; p ¼ 0.001. Although ECV
was also a strong predictor, it was not independent
in the diastolic dysfunction or final combined
model inclusive of the strongest predictors
(Supplemental Table 3).
ASSOCIATIONS OF iECV (AND ECV). Univariate
associations of iECV in HFpEF are shown in Table 4
(see also Supplemental Table 4 for ECV). Because the
calculation of iECV is dependent on LV mass, which
in turn is closely linked with LV volumetric mea-
surements, both of these metrics were excluded from
further analysis. Indeed, the correlations of iECV with
LV mass and left ventricular end-diastolic volume
indexed (LVEDVI) yielded Pearson’s r ¼ 0.888 and r ¼
0.578, respectively (p < 0.0001 for both). For LV mass
correlation with LVEDVI, r was 0.582; p < 0.0001.
Heart rate, systolic blood pressure, diabetes, his-
tory of hypertension, creatinine level, LV mass/vol-
ume, right ventricular end-diastolic volume indexed
(RVEDVI) and LAVImax remained significant on
multivariate analysis. Of those independently asso-
ciated with iECV (Supplemental Figure 1), the stron-
gest correlations were with RVEDVI (r ¼ 0.456;
p < 0.0001), LV mass/volume (r ¼ 0.348; p ¼ 0.001),
creatinine level (r ¼ 0.271; p ¼ 0.009), and LAVImax
(r ¼ 0. 269; p ¼ 0.009).
DISCUSSION
This is the first outcome study to systematically
evaluate fibrotic burden in well-phenotyped cohorts
of HFpEF subjects and control subjects of similar age
and sex, using CMR. Furthermore, iECV was evalu-
ated as a newer marker of diffuse fibrosis for the first
time in HFpEF subjects and this was related to clinical
outcome. The following are the principal findings: 1)
both focal and diffuse fibrosis are elevated in HFpEF
subjects compared to asymptomatic control subjects; 2)
diffuse fibrosis as assessed by iECV independentlypredicted prognosis in HFpEF; and 3) iECV was asso-
ciated with markers of ventricular and left atrial
remodeling, as well as renal dysfunction.
FOCAL FIBROSIS. Overall, there was more focal
fibrosis (ischemic and nonischemic) in HFpEF sub-
jects than in control subjects. New cases of previously
unknown MI were also detected, which were gener-
ally small, in keeping with overall preservation
of LVEF. Unlike the only previous study to demon-
strate independent prediction of outcomes with
LGE-quantified focal fibrosis in HFpEF subjects (10),
the present patients had less burden of nonischemic
fibrosis, and LGE was not related to outcomes. The
reason for this difference may be due to the quanti-
fication method used for focal fibrosis. Although
various semiautomated quantification methods exist,
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the full-width half-maximum technique was used,
which is the most reproducible across the spectrum of
both ischemic and nonischemic causes (21). The pre-
vious study used a threshold of > 2 SD of signalMultivariate Predictor Models Inclusive of iECV for the Composite
of Death and/or Hospitalization With Heart Failure
Hazard Ratio (95% CI) p Value
linical
hospitalization 2.573 (1.135–5.837) 0.024
or COPD 2.085 (0.972–4.473) 0.059
obin, g/l 0.747 (0.525–1.063) 0.105
ml/m2 1.530 (1.107–2.113) 0.010
iastolic Dysfunction
/l 1.020 (0.702–1.484) 0.916
io 1.717 (1.178–2.503) 0.005
x 1.222 (0.894–1.670) 0.209
ml/m2 1.613 (1.111–2.342) 0.012
V Structural/Remodeling
/volume 1.251 (0.905–1.731) 0.176
e of MI 1.590 (0.765–3.307) 0.214
(ml/m2) 1.463 (1.060–2.020) 0.021
Strongest Parameters Combined
hospitalization 2.537 (1.090–5.902) 0.031
or COPD 2.083 (0.883–4.915) 0.094
io 1.716 (1.191–2.472) 0.004
(ml/m2) 1.689 (1.141–2.501) 0.009
nce interval; other abbreviations as in Tables 1 and 2.intensity above remote myocardium to define
fibrosis, which can result in overestimation and
measurement errors from partial volume effects (21),
and in addition, as the ECV in these patients is
diffusely increased, defining normal myocardium is
problematic.
DIFFUSE FIBROSIS. Recently, iECV has been pro-
posed as a novel marker of diffuse fibrosis (15). In a
cohort of patients with aortic stenosis, iECV corre-
lated well with histological fibrosis, discriminated
between patients with disease and healthy control
subjects, and was the only T1 mapping parameter to
differentiate between differing grades of valve ste-
nosis. Furthermore, it demonstrated association with
clinical outcomes (15).
ECV (and iECV) were quantifiable in 97% in the
present subjects and with a high degree of repro-
ducibility, which is clinically relevant. Recently, ECV
was shown to predict outcome in a large retrospective
study (n ¼ 1,172), encompassing all-comers referred
for CMR (22). In that study, ECV analysis was similar
to the present method and predicted outcomes
independently across the whole cohort, regardless of
EF. Similar to the present results, diffuse fibrosis was
more strongly associated with outcomes than non-
ischemic focal fibrosis. However, as well as selection
bias in only recruiting patients referred for clinical
TABLE 4 Univariate and Multivariate Linear Regression Models for the Associations
With iECV
Univariate Analysis Multivariate Analysis
Standardized
Coefficients (Beta) p Value
Standardized
Coefficients (Beta) p Value
Clinical
Heart rate, beats/min 0.188 0.072 0.173 0.025
Males 0.504 <0.0001 - NS
Systolic blood pressure, mm Hg 0.254 0.015 0.230 0.001
BMI, kg/m2 0.230 0.028 - NS
Diabetes 0.181 0.084 0.205 0.005
Hypertension 0.179 0.088 0.162 0.028
Sera values
Creatinine, mmol/l 0.271 0.009 0.196 <0.008
Hemoglobin, g/l 0.188 0.072 - NS
BNP, ng/l 0.449 <0.0001 - NS
CMR
LVEDVI 0.578 <0.0001 - -
LVEDMI 0.888 <0.0001 - -
LV mass/volume 0.348 0.001 0.541 <0.0001
*RVEDVI, ml/m2 0.456 <0.0001 0.538 <0.0001
*RVESVI, ml/m2 0.300 0.004 - -
LAVImax, ml/m2 0.269 0.009 0.264 0.001
Overall multivariate model R2 ¼ 0.657. *Variables which exhibited significant collinearity; of these variables,
RVEDVI (ml/m2) was entered into multivariate analysis. LVEDVI and LVEDMI were not entered into multivariate
analysis.
BMI ¼ body mass index; NS ¼ not significant; other abbreviations as in Tables 1 and 2.
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CMR, the proportion of subjects with clinical HF was
small, and it is unclear how many patients had
HFpEF.
In the present study, although native T1 was also
significantly increased, ECV and iECV were the only
markers of diffuse fibrosis to provide prognostic value
in multivariate analysis. Native T1 values reflect
both intra- and extracellular changes, whereas
post-contrast T1 is subject to a variety of confounders
(8). On the other hand, ECV is effectively a ratio,
taking into account both pre- and post-contrast
values and canceling out systematic biases in T1
measurements. ECV and iECV are therefore more
likely to provide a better reflection of diffuse fibrosis
(9). This is further supported by evidence showing
better correlation of ECV with histologically
measured fibrosis than for native or post-contrast
T1 values (8,9).
To date, only 4 prior prospective studies have
demonstrated the association between diffuse
fibrosis and clinical outcomes in HFpEF. The first
study (12) used post-contrast T1 times as a measure-
ment of diffuse fibrosis in a much smaller cohort of
HFpEF subjects (n ¼ 61) and had the intrinsic limita-
tions outlined above. In the second study (n ¼ 117)
(11), ECV was also associated with adverse events. In
contrast to the present study, focal fibrosis was
defined as myocardial signal intensity of >5 SD above
the mean intensity of healthy myocardium, and such
regions were excluded from ECV calculations.
Furthermore, ECV was associated with outcomes
when confined to CMR parameters only but not in a
combined multivariate model including clinical vari-
ables, unlike the present study in which iECV was
used. In the third study (14), diffuse fibrosis, that is,
elevated ECV, was suggested to precede overt clinical
HFpEF and was also related to outcomes in those
(n ¼ 160) with or who were “at risk” (n ¼ 250) of
HFpEF but in all comers with preserved ejection
fraction referred for clinical CMR, again highlighting
concerns regarding referral bias. In the recently
published final study, ECV independently predicted
adverse outcomes in HFpEF (n ¼ 118). However, the
control group was much smaller (n ¼ 26), and median
follow-up (11 months) was substantially shorter than
that in the present study.
IMPORTANCE OF FIBROTIC ASSESSMENT IN HFpEF.
Our results shed further insight into the pathophysi-
ology of HFpEF, with diffuse fibrosis playing a central
role. Diabetes (23), pressure overload (increasing
systolic blood pressure and/or history of hyperten-
sion) (24) and renal impairment (25) as likely
causative factors for diffuse myocardial fibrosisdevelopment have previously been reported.
Furthermore, this hypothesis is supported by epide-
miological and clinical trial data. whereby HFpEF is
heavily laden with such co-morbidities (2). Myocar-
dial fibrosis is further intrinsically linked to LV stiff-
ness and chamber modification, which likely explains
the greater adverse remodeling and diastolic
dysfunction seen in the present predominantly hy-
pertensive HFpEF cohort (5,26). Additionally, right
ventricular and left atrial remodeling are likely
downstream consequences (27).
Previous studies have also highlighted the associ-
ation between ECV and strain measurements of both
systolic and diastolic dysfunctions in hypertensive
LVH subjects at risk of developing HFpEF (28). In a
recent small study, ECV was the imaging parameter
that best discriminated between HFpEF (n ¼ 62)
and hypertensive (n ¼ 22) heart disease subjects (29).
The independent associations between iECV with
LAVImax and serum creatinine in the present study
are also similar to results from the PARAMOUNT
study of HFpEF (30). In that trial, ST2, galectin-3,
matrix metalloproteinase-2, and collagen type III
N-terminal propeptide as surrogate plasma markers
of fibrosis (and the extracellular matrix) also corre-
lated strongly with left atrial volume and renal
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
HFpEF is seen in up to 50% of patients hospitalized
for heart failure and is associated with a poor
prognosis but no definite treatments. Using CMR, the
present study shows that patients with HFpEF have
increased levels of diffuse and focal fibrosis
associated with concentric remodeling and diastolic
dysfunction. In HFpEF, diffuse fibrosis assessed using
a new marker (indexed extracellular volume) was
independently associated with adverse prognosis and
may be useful in future risk stratification of these
patients.
TRANSLATIONAL OUTLOOK: As diffuse fibrosis is
reversible, randomized controlled trials of interven-
tions to reduce diffuse fibrosis should be considered
to prevent and potentially treat HFpEF.
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Interestingly, unlike the aforementioned study, our
data shows that iECV did not correlate with E/E0 or
natriuretic peptides, which may partly be explained
by the differing fluid status of subjects, most of whom
invariably had a period of offloading with diuretics
prior to CMR as part of routine clinical care (24,31).
iECV appears to detect diseased myocardium not
readily apparent with LGE, which was not associated
with outcome. Unlike irreversible replacement
fibrosis identified by LGE, diffuse fibrosis may be
reversible and therefore a potential therapeutic target
(22). The present work lends further support to a
growing body of evidence highlighting ECV (and
iECV) as promising biomarkers across a spectrum of
cardiac pathologies. Furthermore, their association
with outcomes appears stronger than conventional
LGE assessment, which has historically been more
extensively studied (9,22).
In the present cohort, iECV was a more powerful
predictor of outcomes, even compared to ECV. This is
most likely because iECV depends upon LV mass for
calculation, which in turn is closely linked to LV
volumes, all of which have been linked previously
with outcomes (26).
STUDY LIMITATIONS. Although the authors’ defini-
tion of HFpEF was not in accordance with the latest
European Society of Cardiology guidelines (32), a
pragmatic approach was taken to reflect a real-world
setting. In particular, diastolic dysfunction was not
a prerequisite for study entry because it is reportedly
absent in nearly one-third of contemporary HFpEF
clinical trials and conversely also identified in a sig-
nificant proportion of asymptomatic elderly subjects
(33). As the iECV data have been acquired only once,
causality between causes of increased iECV cannot be
inferred. The full-width half-maximum technique for
quantification of LGE was used, which may allow
comparison with other studies using this technique,
but it should be borne in mind that significant vari-
ability arises from drawing LV contours (34). A pro-
portion of consecutive trial subjects (nearly 24%) who
underwent CMR did not undergo MOLLI imaging due
to the sequence not being available (i.e., not per-
formed). This may have introduced potential bias.However, a comparison between the HFpEF group
who underwent MOLLI imaging and those who did
not (Supplemental Table 5) revealed no major differ-
ences in baseline clinical characteristics, providing
strong support that our results are likely representa-
tive across the whole cohort.
CONCLUSIONS
Focal and diffuse fibrosis are more prevalent in
HFpEF subjects than in healthy control subjects of
similar age and sex. Diffuse fibrosis as assessed by
iECV in HFpEF correlates with markers of biven-
tricular and left atrial remodeling as well as renal
dysfunction and is an independent predictor of
adverse outcomes in HFpEF.
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